

DICHIARAZIONE DI ACCETTAZIONE DELLA CANDIDATURA ALLA CARICA DI AMMINISTRATORE DI GENENTA SCIENCE S.P.A. E ATTESTAZIONE DELL'INESISTENZA DI CAUSE DI INELEGGIBILITÀ E INCOMPATIBILITÀ E DEL POSSESSO DEI REQUISITI RICHIESTI.


Il sottoscritto Dott. Salvatore Calabrese, nato a Locri (RC), il 4 gennaio 1970, C.F. CLBSVT70A04D976G, residente in Milano, via Quintino Sella 2,

premessò che

- è stato indicato quale candidato alla carica di Amministratore di Genenta Science S.p.A., con sede legale in Milano, Via dell'Annunciata n. 31, codice fiscale n. 08738490963 (la "Società" o "Genenta") in relazione alla nomina del Consiglio di Amministrazione della Società prevista all'ordine del giorno della prossima Assemblea Ordinaria degli Azionisti convocata per il giorno 29 giugno 2026, ore 17, in prima convocazione e, occorrendo, in seconda convocazione per il giorno 30 giugno 2026, ore 17:30;

dichiara e attesta sotto la sua responsabilità

- di non essere candidato in altra lista presentata in occasione della citata Assemblea;
- di accettare la candidatura e l'eventuale nomina alla carica di Amministratore della Società;
- l'inesistenza di cause di ineleggibilità, decadenza e/o incompatibilità previste dalla normativa vigente per l'assunzione della carica di Amministratore della Società (incluse quelle di cui all'art. 2382 c.c. italiano, vale a dire interdizione, inabilitazione, fallimento, condanna a pena che importa l'interdizione anche temporanea dai pubblici uffici o l'incapacità ad esercitare uffici direttivi) e/o previste dallo statuto di Genenta;
- di non essere soggetto a interdizioni dall'ufficio di amministratore adottate nei suoi confronti in uno Stato membro dell'Unione Europea;
- di essere informato, ai sensi e per gli effetti di cui al Regolamento UE 2016/679 e al D. Lgs. 30 giugno 2003 n. 196, che i dati personali raccolti saranno trattati dalla Società, anche con strumenti informatici, nel procedimento nell'ambito del quale la presente dichiarazione viene resa e, nel caso di nomina, ai fini degli incombeni legati alla carica, autorizzando la Società a procedere con le pubblicazioni di legge per tali finalità;
- di autorizzare fin d'ora la pubblicazione del *curriculum vitae*, allegato alla presente, atto a fornire esauriente informativa sull'esperienza professionale e le caratteristiche personali.

MILANO, 31 maggio 2026


Dott. Salvatore Calabrese

DECLARATION OF ACCEPTANCE OF NOMINATION FOR THE POSITION OF DIRECTOR OF GENENTA SCIENCE S.P.A. AND CERTIFICATION OF THE ABSENCE OF GROUNDS FOR INELIGIBILITY OR INCOMPATIBILITY AND OF THE FULFILLMENT OF THE REQUIRED QUALIFICATIONS.

The undersigned, Dr. Salvatore Calabrese, born in Locri (RC) on 4 January 1970, Tax ID CLBSVT70A04D976G, residing in Milan, via Quintino Sella 2,


whereas

- he has been nominated as a candidate for the position of Director of Genenta Science S.p.A., with registered office in Milan, Via dell'Annunciata No. 31, tax identification number 08738490963 (the "**Company**" or "**Genenta**") in connection with the appointment of the Company's Board of Directors scheduled on the agenda of the upcoming Ordinary Shareholders' Meeting convened for 29 June 2026, at 17 p.m., on first call, and, if necessary, on second call for 30 June 2026, at 17:30 p.m.;

declares and certifies under his responsibility

- that he is not a candidate on any other slate submitted at the aforementioned Shareholders' Meeting;
- that he accepts his nomination and any subsequent appointment to the position of Director of the Company;
- that there are no grounds for ineligibility, disqualification, and/or incompatibility under applicable laws for assuming the position of Director of the Company (including those referred to in Article 2382 of the Italian Civil Code, namely "*interdizione*", "*inabilitazione*", bankruptcy or a penalty resulting in disqualification – even temporary – from public office or the inability to hold executive positions) and/or under the Company's bylaws;
- that he is not subject to any disqualifications from serving as a director imposed against him in a Member State of the European Union;
- that he has been informed, in accordance with and for the purposes of EU Regulation 2016/679 and Legislative Decree No. 196 of June 30, 2003, that the personal data collected will be processed by the Company, including by electronic means, in the proceedings within the scope of which this declaration is made and, in the event of appointment, for the purposes of the duties associated with the position, authorizing the Company to proceed with the publications required by law for such purposes;
- to authorize, effective immediately, the publication of the curriculum vitae attached hereto, which provides comprehensive information on professional experience and personal characteristics.

MILANO _____, 31 May 2026


Dott. Salvatore Calabrese

Profile

From January 2024, Salvatore Calabrese, is Chief Financial Officer at BetaGlue Therapeutics S.p.A. a clinical-stage oncology company developing a novel radiotherapy platform for the localized and targeted treatment of unresectable solid tumors. BetaGlue has been financed by leading Italian VC's, European Innovation Council Accelerator and by an Italian private Foundation supervised by the Italiana Ministry of Enterprises. In his role, he is responsible for legal, admin, finance, information technology, tax, human resources and corporate governance. He helped to raise 21.5 million Euro in funds from private and public sector. He is listed in the Italian National Audit Register held by the National Justice Department (registration number 118553).

From October 2020 to April 2023, he was Chief Financial Officer at Gain Therapeutics Inc. (NASDAQ: GANX) a biotechnology company developing small molecule therapeutics to treat disease across several therapeutics areas, including lysosomal storage disorders, central nervous system, metabolic disorders and oncology. In his role, he was responsible for establishing, monitoring and overseeing accounting, finance, tax and transfer price, consolidated financial statements in local and US GAAP, financial reporting, cash-flows and forecasting, internal control for the organization. His responsibilities also included the preparation and filing of quarterly and annual SEC filings and supervising the implementation and the validation of the Company's ERP. He helped to raise 60 million USD in funds to develop the Company from both the private sector and the public sector and was instrumental for the listing of the company on the Nasdaq GM.

From September 2018 to September 2020, he was Chief Financial Officer and Officer Responsible for the preparation of corporate financial reports of Molmed SpA (MLMD.MI) a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. In his role, he oversees administration, financial reporting, tax, internal control, procurements and information technology and instrumental for the sale of Molmed SpA to AGC Biologics SpA per Euro 240 million.

From February 2014 to September 2018, he was General Manager and Site Leader of Jazz Pharmaceutical Plc (Nasdaq: JAZZ, market cap >\$9bn) Italian operations. In his role, he was responsible for operation excellence and lean manufacturing, human resources, GMP manufacturing, health, safety and environment, administration, financial reporting, tax, legal, procurements, information technology and internal controls. He has been member of the Board of Directors of Gentium S.r.l, Jazz Healthcare Italy S.r.l. and Member of the Council Chamber of the Industry Group, Unindustria Como, Confindustria Territorial Organization.

Previously, he was SVP Chief Financial Officer & Chief Operations Officer of Gentium S.p.A. (NASDAQ: GENT), an Italian biotech company acquired in 2014 by Jazz Pharmaceuticals Plc for an all cash transaction of 1 billion USD. He joined Gentium in 2005 as VP Finance and was instrumental in the transition of Gentium from a privately held company to a publicly listed biopharmaceutical company initially on AMEX and subsequently on NASDAQ. During this process, he was the primary contact with external auditors, statutory auditors and legal counsels and Secretary of the Board of Directors. He has also been responsible for corporate governance, human resources, collaboration with the M&A team, overview of a GMP manufacturing facility, health, safety, environment and business development. Additionally, in his role as the CFO he has been responsible for establishing, monitoring and overseeing accounting, finance, tax and transfer price, financial statements in local and US GAAP, financial reporting, cash flow and forecasting, insurance, procurement, internal control, IT&C, legal affairs for the organization. His responsibilities have also included the preparation and filing of quarterly and annual SEC filings and supervising the implementation and the validation of the Company's ERP. He has contributed to develop and implement strategy across the

"Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi dell'art. 13 del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e dell'art. 13 del GDPR (Regolamento UE 2016/679)."

organization and help execute staff succession and growth plans and development including set-up a subsidiary in Switzerland. He has helped to raise close to 130 million USD in funds to develop the Company from both the private sector and the public sector.

From December 2003 to February 2005, he was Accounting and Finance Manager at Novuspharma SpA (NOV:MI) and then at Cell Therapeutics Inc (NASDAQ: CTIC), a biotech company that develops, acquires and commercializes novel treatments for cancer. On January 1, 2004, CTI completed the acquisition of Novuspharma SpA, an Italian biotech company focused on oncology. His responsibilities included monthly/quarterly reports and annual close, cash management and expense control and he championed the implementation of Sarbanes-Oxley compliance.

From September 1996 to November 2003, he worked at PricewaterhouseCoopers as Manager in the Assurance Business Advisory Service practice in Milan and in Boston, where he lived from October 2000 to June 2003 and worked as Senior Auditor specialized in audit and business review of Start-up Companies (Venture capital owned) and Public Companies listed on NASDAQ and on NYSE (Biotech and media market segment specialization). His duties included compliance reviews under US GAAP and SEC regulations, review of quarterly and annual filings, public offering (S1 form) and collocation on debt through the public. In Milan, he worked in audit engagement of Public Companies listed in the Italian Stock Exchange under Consob regulations, reporting package for US subsidiaries operating in the Italian market environment.

Personal information

Name and Surname: Salvatore Calabrese
Date and place of birth: Locri (RC), 04/01/1970
Residence: Via Quintino Sella, 2, 20121 Milano - Italy
Citizenship: Italian

Languages Italian, English,**Education**

2023 Harvard Business School Online – Strategy Execution

2023 Harvard Business School Online – Certificate Program on Leadership Principles

2017 Lean Manufacturing live experience with Lean Sensei, Japan Tour.

2012-2013 SDA Bocconi University, Milan. Transfer Price Course.

1995-1996 Master's Degree in *Accounting, Audit and Financial Control* at the University of Pavia. Project-work and internship at Price Waterhouse, Milan Office. Discussed a thesis on the audit approach of property, plan and equipment of an Industrial Company.

1994-1995 *Bachelor's Degree in Economics* held at the University of Messina. Discussed a thesis on the Business Model and Characteristics of a non-profit organization.

1992-1993 *10 months Erasmus Project* in the Business & Management Department at "The University of Ulster at Coleraine" (Northern Ireland). Main topics: Business Organization, Human Resource Management, Marketing and Retailing.

Professional experience

- January 2024-current* BetaGlue Therapeutics S.p.A., Chief Financial Officer
- Sept. 2020 – April 2023* Gain Therapeutics. (Nasdaq: GANX): MI), Chief Financial Officer & Principal Accounting Officer.
- Sept. 2018, Sept 2020* Molmed S.p.A. (MLMD: MI), Chief Financial Officer & Officer Responsible for the preparation of corporate financial reports.
- Sept. 2014/Sept 2018* Gentium S.r.l, General Manager and Site Leader of the Italian Operations of Jazz Pharmaceuticals Plc. Member of the Board of Director of Gentium S.r.l and Jazz Healthcare Italy S.r.l.
- Oct.2013/Aug.2014* Gentium S.p.A. (NASDAQ: GENT), SVP Chief Financial Officer & Chief Operations Officer.
- Dec.2010/Oct.2013* Gentium S.p.A. (NASDAQ: GENT), SVP Finance & Chief Financial Officer.
- Feb.2005/Dec.2010* Gentium S.p.A. (NASDAQ: GENT), VP Finance.
- Dec.2003/Feb.2005* Novuspharma SpA (NOV:MI), Cell Therapeutics Inc. (NASDAQ:CTIC), Accounting and Finance Manager.
- July 2003/Dec.2003* PricewaterhouseCoopers, Milan Office, Assurance Business Advisory Service, Manager.
- Oct.2000-June 2003* PricewaterhouseCoopers, Boston Office, Assurance Business Advisory Service, Audit, Senior Audit
- Sept.1996-Sept. 2000* Pricewaterhouse, Milan Office, Audit, Transaction Support & Business Review, Senior Auditor.

Other

Instructor at PricewaterhouseCoopers Italian Formation Centre, held seminars at the University of Pavia in the Master Degree Course on Accounting, Audit and Financial Controls. Presented the following topics: Italian GAAS and GAAP, analysis of the internal control system, risk analysis, managing the audit project.

Unindustria Como, Confindustria Territorial Organization, member of the Council Chamber and of the Industry Group.

Strong communication skills, enthusiasm, and an undying passion to succeed. Self-motivated with the ability to guide and manage. Positive, and decisive individual with a high level of energy. Organized, an effective coach and mentor, who leads by example. A hands-on manager with integrity and a desire to work in a dynamic, mission-driven environment.